BusinessAbeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis BullosaBy Nasdaq OMXMay 25, 2017, 12:10 PM UTC
BusinessAbeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis BullosaBy Nasdaq OMXMay 25, 2017, 12:10 PM UTC
BusinessAbeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis BullosaBy Nasdaq OMXMay 25, 2017, 12:10 PM UTC
BusinessAbeona Therapeutics Announces Top-Line Data for ABO-102 Phase 1/2 MPS IIIA Gene Therapy Trial at ASGCTBy Nasdaq OMXMay 12, 2017, 12:05 PM UTC
BusinessAbeona Therapeutics Receives Regulatory Approval to Initiate Clinical Trial in Australia with ABO-102 Gene Therapy For Patients with MPS IIIABy Nasdaq OMXMay 9, 2017, 12:05 PM UTC
BusinessAbeona Announces Rare Disease Gene Therapy Symposium with the New York Academy of SciencesBy Nasdaq OMXApr 5, 2017, 11:43 AM UTC
